TX SB1827

Adds requirement that investigational stem cell treatments must use only adult stem cells that satisfy current good manufacturing practices adopted by the FDA

Expands approved treatment locations to include outpatient settings registered to provide level II anesthesia services, in addition to hospitals, ambulatory surgical centers, and medical schools

Requires informed consent forms to include notice that the investigational stem cell treatment has not been approved for general use by the FDA

Modifies annual reporting requirements for institutional review boards to specifically include reports on any serious adverse events related to the treatment

Removes requirement that annual reports be made available to the public in written and electronic form, though reports must still be submitted to the Texas Medical Board